172 related articles for article (PubMed ID: 26341695)
41. Development of a ¹⁷⁷Lu-labeled RGD derivative for targeting angiogenesis.
Ju CH; Jeong JM; Lee YS; Kim YJ; Lee BC; Lee DS; Chung JK; Lee MC; Jeong SY
Cancer Biother Radiopharm; 2010 Dec; 25(6):687-91. PubMed ID: 21204763
[TBL] [Abstract][Full Text] [Related]
42. [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts.
Persson M; Gedda L; Lundqvist H; Tolmachev V; Nordgren H; Malmström PU; Carlsson J
Cancer Res; 2007 Jan; 67(1):326-31. PubMed ID: 17210714
[TBL] [Abstract][Full Text] [Related]
43. Cancer theranostic applications of lipid-based nanoparticles.
Tang WL; Tang WH; Li SD
Drug Discov Today; 2018 May; 23(5):1159-1166. PubMed ID: 29660478
[TBL] [Abstract][Full Text] [Related]
44. Novel series of (177)Lu-labeled bombesin derivatives with amino acidic spacers for selective targeting of human PC-3 prostate tumor cells.
Pujatti PB; Santos JS; Couto RM; Melero LT; Suzuki MF; Soares CR; Grallert SR; Mengatti J; De Araújo EB
Q J Nucl Med Mol Imaging; 2011 Jun; 55(3):310-23. PubMed ID: 21532543
[TBL] [Abstract][Full Text] [Related]
45. Design, preparation, and in vitro characterization of a trimodally-targeted nanomagnetic onco-theranostic system for cancer diagnosis and therapy.
Zarrin A; Sadighian S; Rostamizadeh K; Firuzi O; Hamidi M; Mohammadi-Samani S; Miri R
Int J Pharm; 2016 Mar; 500(1-2):62-76. PubMed ID: 26721723
[TBL] [Abstract][Full Text] [Related]
46. Multifunctional calcium phosphate nanoparticles for combining near-infrared fluorescence imaging and photodynamic therapy.
Haedicke K; Kozlova D; Gräfe S; Teichgräber U; Epple M; Hilger I
Acta Biomater; 2015 Mar; 14():197-207. PubMed ID: 25529187
[TBL] [Abstract][Full Text] [Related]
47. Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues.
Kevadiya BD; Ottemann B; Mukadam IZ; Castellanos L; Sikora K; Hilaire JR; Machhi J; Herskovitz J; Soni D; Hasan M; Zhang W; Anandakumar S; Garrison J; McMillan J; Edagwa B; Mosley RL; Vachet RW; Gendelman HE
Theranostics; 2020; 10(2):630-656. PubMed ID: 31903142
[TBL] [Abstract][Full Text] [Related]
48. In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.
Almqvist Y; Steffen AC; Tolmachev V; Divgi CR; Sundin A
Nucl Med Biol; 2006 Nov; 33(8):991-8. PubMed ID: 17127172
[TBL] [Abstract][Full Text] [Related]
49. Quercetin Remodels the Tumor Microenvironment To Improve the Permeation, Retention, and Antitumor Effects of Nanoparticles.
Hu K; Miao L; Goodwin TJ; Li J; Liu Q; Huang L
ACS Nano; 2017 May; 11(5):4916-4925. PubMed ID: 28414916
[TBL] [Abstract][Full Text] [Related]
50. Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin.
Dumont RA; Tamma M; Braun F; Borkowski S; Reubi JC; Maecke H; Weber WA; Mansi R
J Nucl Med; 2013 May; 54(5):762-9. PubMed ID: 23492884
[TBL] [Abstract][Full Text] [Related]
51. Comparative biodistributions and dosimetry of [¹⁷⁷Lu]DOTA-anti-bcl-2-PNA-Tyr³-octreotate and [¹⁷⁷Lu]DOTA-Tyr³-octreotate in a mouse model of B-cell lymphoma/leukemia.
Balkin ER; Liu D; Jia F; Ruthengael VC; Shaffer SM; Miller WH; Lewis MR
Nucl Med Biol; 2014 Jan; 41(1):36-42. PubMed ID: 24267052
[TBL] [Abstract][Full Text] [Related]
52. Demonstration of dose dependent cytotoxic activity in SW480 colon cancer cells by ¹⁷⁷Lu-labeled siRNA targeting IGF-1R.
Fathi M; Taghikhani M; Ghannadi-Maragheh M; Yavari K
Nucl Med Biol; 2013 May; 40(4):529-36. PubMed ID: 23618769
[TBL] [Abstract][Full Text] [Related]
53. Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
Yordanov AT; Hens M; Pegram C; Bigner DD; Zalutsky MR
Nucl Med Biol; 2007 Feb; 34(2):173-83. PubMed ID: 17307125
[TBL] [Abstract][Full Text] [Related]
54.
Kumar C; Sharma R; Das T; Korde A; Sarma H; Banerjee S; Dash A
J Labelled Comp Radiopharm; 2018 Sep; 61(11):837-846. PubMed ID: 29923620
[TBL] [Abstract][Full Text] [Related]
55. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
[TBL] [Abstract][Full Text] [Related]
56. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
Mulligan T; Carrasquillo JA; Chung Y; Milenic DE; Schlom J; Feuerstein I; Paik C; Perentesis P; Reynolds J; Curt G
Clin Cancer Res; 1995 Dec; 1(12):1447-54. PubMed ID: 9815943
[TBL] [Abstract][Full Text] [Related]
57. Tumor-Targeting Multifunctional Rattle-Type Theranostic Nanoparticles for MRI/NIRF Bimodal Imaging and Delivery of Hydrophobic Drugs.
Jiao Y; Sun Y; Tang X; Ren Q; Yang W
Small; 2015 Apr; 11(16):1962-74. PubMed ID: 25504837
[TBL] [Abstract][Full Text] [Related]
58. In vitro and in vivo evaluation of 177Lu- and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers.
Giblin MF; Sieckman GL; Shelton TD; Hoffman TJ; Forte LR; Volkert WA
Nucl Med Biol; 2006 May; 33(4):481-8. PubMed ID: 16720239
[TBL] [Abstract][Full Text] [Related]
59. Effect of
Azorín-Vega E; Aranda-Lara L; Torres-García E; Santiago-Bañuelos JA
Appl Radiat Isot; 2019 Apr; 146():24-28. PubMed ID: 30743222
[TBL] [Abstract][Full Text] [Related]
60. Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis.
Huang S; Shao K; Liu Y; Kuang Y; Li J; An S; Guo Y; Ma H; Jiang C
ACS Nano; 2013 Mar; 7(3):2860-71. PubMed ID: 23451830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
